Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed.
We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grantdisclosure patterns. Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor. No HAO disclosed the exact amount of a Lilly grant.
As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. In addition, HAOs advocate for members' unrestricted access to all drugs, devices, and diagnostic tools relevant to their health conditions, almost always favoring branded drugs over generics, new screening technologies over older ones, and open formularies rather than closed ones. These positions closely correspond to the marketing aims of pharmaceutical and device companies; each position would help to increase product sales. Yet, despite the overlapping interests of HAOs and the pharmaceutical industry, the financial relationships between them have remained relatively unexplored. We conducted the current study in an effort to fill this knowledge gap.
This investigation is feasible because data on industry contributions to HAOs have recently become publicly available, which allows for an examination of HAOs' disclosure practices. In response to US Department of Justice criminal prosecutions and state legislative mandates, some drug and device companies now report on their Web sites the precise dollar amounts of the grants and gifts they make to HAOs. Thus, it is now possible to analyze which HAOs the industry selects for funding and the HAOs' degrees of transparency in reporting that funding.
We selected Eli Lilly and Company for analysis because it was the first company to make its grant registry public. The Lilly registry identifies the HAOs receiving support and the exact level of support each HAO receives. Lilly's registry provides specific information about the company's grant-giving policies and practices; this information is made even more useful when supplemented by Lilly's financial reports on its best-selling drugs. On the other side of the grant equation, it would be reasonable to expect HAOs to be fully transparent about their grantors, given the credibility that HAOs enjoy. An examination of the Web sites of the HAOs that received funding from Lilly makes it possible to determine the degree to which each HAO has disclosed its Lilly funding.
ACTIVITIES OF HEALTH ADVOCACY ORGANIZATIONS
HAOs range in size from national organizations with thousands of members concerned with a widespread disease (diabetes, cancer) to smaller organizations that have a narrower focus (alpha-1 antitrypsin deficiency, trisomy 18). Typically, HAOs conduct campaigns to promote disease awareness, update members about new diagnostic tests and drugs, facilitate physician referrals, deliver health care services, and advocate for policies that they believe are in their members' best interests. HAO leaders and members testify at congressional and state hearings, lobby legislators, negotiate with regulators, serve on federal advisory panels, and inform the media.
HAOs are highly effective advocates, deftly putting a human face on advocacy around a particular disease. As an oncology journal editorial explained, ''There is one activity that lobbyists or public relations firms, no matter how well paid, will never be able to perform in place of advocacy groups. This is the ability to acknowledge what it actually means to be a cancer patient.'' ; and media exposés of some HAOs' dependence on drug company funding. 8, 9 HAOs' advocacy agenda overlaps with industry marketing interests, making the need to evaluate disclosure practices more urgent. 10, 11 ''A message's credibility is greater when delivered by impartial third parties than by entities seeking to profit from it,'' observed a public relations firm. ''Advocacy groups who know a company and its values can be counted on to speak out for it and relevant issues in times of need.'' 12 Although HAOs are not legally required to disclose the names of their corporate sponsors, their advocacy activities and the level of public trust that they enjoy makes transparency more obligatory.
THE CHANGED MISSION OF HEALTH ADVOCACY ORGANIZATIONS
Organizations that once served the public interest have become devoted to their members' interests. This transformation also enhances the need to evaluate levels of transparency. In the opening decades of the 20th century, philanthropic citizens joined with public health officials and civicminded physicians to spearhead campaigns against deadly diseases. 13 Although each organization targeted a specific disease, they allied to advance sweeping social changes. 24, 25 We obtained the data for this study from the LGR. Because we wanted to identify an unobtrusive measure for our analysis of disclosure patterns before HAO policies might be affected by pharmaceutical companies' disclosures, we selected Lilly, the first pharmaceutical company to publicly release its grant registry, and examined its grant giving and the grants it awarded to HAOs during the first 2 quarters of 2007. We designed data-collection methods that made maximum use of the publicly available information about Lilly's grant-giving criteria and the detailed funding information in the LGR. 24 First, we analyzed Lilly's funding criteria. Lilly's Grant Office specified the therapeutic areas for which Lilly would accept grant requests and the types of programs it would support. One area so identified was ''patient advocacy and consumer education programs.'' 26 Lilly's grants policy, as specified in the LGR, was not to make ''unrestricted educational grants''; rather, ''the purpose of the grant must be designated,'' and awarded funds could only be used for the stated grant purpose. 26 To determine whether there were links between Lilly's grant giving and its marketing goals, we gathered information from the company's 2007 annual report on the net sales of its bestselling pharmaceutical products and the aggregated net sales for each of the company's therapeutic areas. 27 Second, we used the LGR information to compile a list of HAOs receiving Lilly grants. We defined HAOs as not-for-profit organizations concerned with health care in which both the leadership and membership were drawn predominantly from the general public. The LGR listed 188 organizations that met these criteria. They included groups concerned with specific diseases and disabilities and with general health issues. National organizations, chapters of national organizations, and regional, state, county, and community organizations were represented. We then organized the information obtained from the LGR about HAOs' grant awards, making use of the following LGR categories:
The name of the HAO that received the award. 27 Lilly pharmaceuticals cover 6 therapeutic areas: neurosciences (mental disorders and disabilities and neurologic disorders), oncology, endocrinology, cardiovascular, animal health, and other pharmaceuticals. 27 We obtained infor- We used the information collected from the click search of HAO Web sites to create 4 dichotomous yes/no variables: (1) Lilly was acknowledged in the HAO's 2007 annual report, (2) Lilly was acknowledged on a corporate sponsors page, (3) Lilly was acknowledged as a grant event sponsor, and (4) the amount of the Lilly grant was reported. A fifth variable, ''Lilly acknowledged anywhere,'' was a summary of the 4 variables. We used SPSS version 16 (SPSS, Chicago, IL) to perform statistical analysis on the data.
RESULTS
Examination of the LGR information revealed that during the first 2 quarters of 2007, Lilly gave $3 211144 to HAOs, representing 10.22% of its total grant giving. The funding was closely aligned with the company's therapeutic areas of interest. HAOs active in Lilly's 3 main therapeutic areas (accounting for 87% of its total US sales)-neurosciences, endocrinology, and oncology-received 94% of Lilly's grants to HAOs. The match of therapeutic area to HAO was not consistent; neuroscience and oncology HAOs received proportionately more grant funds than Lilly's sales percentages in these therapeutic areas, and endocrinology received less. But overall it was evident that the company targeted HAOs concerned with its areas of therapeutic interest.
Grants Made by Therapeutic Area
Lilly's grants to HAOs also mirrored its therapeutic areas with the strongest sales. In 2007, Lilly reported annual US net sales of $10145 500 000. 27 Of this total, 45% came from neurosciences, 31% from endocrinology, 11% from oncology, and 13% from miscellaneous health ( Figure 1 
Lilly Funding Acknowledged on Web Sites
Of the 161 sample HAOs that received Lilly funding, 137 (85%) were in neurosciences (n =114), endocrinology (n = 6), and oncology (n =17). In terms of geographic scope, endocrinology and oncology HAOs were predominantly national organizations. Specifically, 4 of the endocrinology HAOs that received funding had a national scope, and 2 were chapters of national organizations. Similarly, 13 of the oncology HAOs were national, 1 was a chapter, and 3 had a regional or local scope. The neurosciences and miscellaneous health categories of HAOs had organizations in all 3 geographic scope categories. For the neuroscience HAOs, the majority (n= 93) were chapters, 11 were national, and 10 were regional or local. Most of the HAOs in the miscellaneous health category were either national (n=12) or regional or local (n=10); only 2 were chapters.
As an aggregate, 25% of HAOs acknowledged Lilly funding anywhere on their Web site. Eighteen percent acknowledged Lilly in their 2007 annual report, 1% acknowledged Lilly on a corporate sponsors page, and 10% acknowledged Lilly as the sponsor of the grant event reported in the LGR (Table 1) .
Grant Disclosure by Therapeutic Area
We then explored HAO disclosure information by Lilly's therapeutic areas.
Neurosciences. 
Neuroscience Disclosure by Geographic Scope
National organizations were the most common type of grant recipient for the oncology, endocrinology, and miscellaneous health HAOs. However, sufficient diversity the neuroscience HAOs differed sufficiently to examine disclosure of Lilly funding by HAO geographic scope, e.g., national, chapter, or other ( Table 2) .
National organizations. Of the 11 national neuroscience HAOs, 36% acknowledged Lilly anywhere on their Web site. Sixtyfour percent acknowledged Lilly in their annual report, 18% acknowledged Lilly on a corporate sponsors page, and 55% listed Lilly as a grant event sponsor. None disclosed the amount of the grant.
Chapters. Of the 93 neuroscience chapters, 88 were chapters of 2 national organizations: the National Alliance on Mental Illness (NAMI) and Mental Health America. Fourteen percent of the chapters acknowledged Lilly on their Web site. Four percent acknowledged Lilly in their annual report, 1% acknowledged Lilly on a corporate sponsors page, and 1% acknowledged Lilly as a grant event sponsor. One chapter, Mental Health America of Southeastern Pennsylvania, disclosed the amount of funding and reported it as a range.
Other organizations. Of the 10 neuroscience county and regional HAOs, 30% acknowledged Lilly anywhere on their Web site. Twenty percent acknowledged Lilly in their annual report, none acknowledged Lilly on a corporate sponsors page, and 10% acknowledged Lilly as a grant event sponsor. None disclosed the amount of the Lilly grant.
There was no significant difference in the neuroscience HAO disclosure rates among national, chapter, and other organizations (c 2 [2] = 4.58; P = .101).
DISCUSSION
Lilly's grants went primarily to HAOs working in its areas of therapeutic interest and in areas related to its best-selling products. Lilly has acknowledged this type These limits recognized, the disclosure patterns we reported are not likely to be unique. The National Health Council, an industry-funded umbrella organization of HAOs, promulgated principles that did not encourage transparency. ''Companies are increasingly basing decisions regarding relationships with not-forprofit organizations on whether these relationships support business goals,'' it informed members. Rather than give guidance on procedures to avoid or manage conflicts of interest, the National Health Council told HAOs ''to enhance their ability to accomplish their mission in areas where the interest of the not-for-profit and the for-profit organizations overlap.'' The organization acknowledged the ''possible negative impact [on] . . . public image and integrity, whether real or imagined,'' so it concluded that HAOs should ''disclose financial and other benefits it receives from a corporate relationship, when asked.'' 38
Conclusions
HAOs are powerful stakeholders in shaping health policies, and they enjoy considerable public trust. Thus, they should become far more detailed in disclosing corporate grants, including the grant's purpose and amount. HAOs should also disclose their industry relationships when testifying before legislative or regulatory committees, serving on advisory panels, and communicating with the media.
Absent substantial changes in HAO reporting practices, state and federal regulations should require that HAO-industry relationships become transparent. To this end, the Sunshine Act provisions in the recently enacted US health reform law, which require companies to report gifts to physicians, should be amended to include company payments to HAOs. Federal income tax regulations should also mandate public disclosure of HAO donors and sums on Form 990. If these changes were implemented, legislators, regulators, and the public would more easily be able to follow the money and evaluate possible biases and conflicts of interest in HAO advocacy.j 
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